- Motley Fool•5 hours ago
It's hard to see why the market has treated shares of Gilead Sciences and First Solar so poorly.
- Forbes•6 hours ago
President Trump's tweets on drug pricing are followed by drops in the stock prices of pharmaceutical companies. Rahul Garg is buying quality companies like Gilead when the President's tweets put them temporarily on sale.
- Forbes•7 hours ago
Regeneron's billionaire chief executive Leonard Schleifer has said that the drug industry's pricing is "ridiculous." So when his own new drug, Dupixent for eczema, was approved, he took an unorthodox path to setting its $37,000-a-year list price.
GILD : Summary for Gilead Sciences, Inc. - Yahoo Finance
Gilead Sciences, Inc. (GILD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||67.07 x 1900|
|Ask||67.19 x 200|
|Day's Range||66.80 - 67.48|
|52 Week Range||65.38 - 103.10|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||6.75|
|Dividend & Yield||2.08 (3.08%)|
|1y Target Est||N/A|